Adrenocortical Carcinoma

Steven E. Rodgers, Douglas B. Evans, Jeffrey E. Lee, Nancy D. Perrier

Research output: Contribution to journalReview articlepeer-review

18 Scopus citations


ACC is a rare clinical entity that carries a poor prognosis; early diagnosis and complete surgical resection are associated with improvement in patient survival. Even with appropriate diagnosis and treatment, most patients will develop recurrence and succumb to ACC because of the underlying tumor biology, the difficulty of achieving a complete resection, and the lack of effective systemic therapies. Despite its many drawbacks, mitotane continues to be a mainstay in the treatment of high-risk patients with ACC, especially those with recurrent or metastatic disease. Recent findings suggest that mitotane, combined with conventional chemotherapeutic agents, may improve survival for such patients.

Original languageEnglish (US)
Pages (from-to)535-553
Number of pages19
JournalSurgical oncology clinics of North America
Issue number3
StatePublished - Jul 1 2006
Externally publishedYes

ASJC Scopus subject areas

  • Surgery
  • Oncology


Dive into the research topics of 'Adrenocortical Carcinoma'. Together they form a unique fingerprint.

Cite this